PT - JOURNAL ARTICLE AU - Luca Quartuccio AU - Arianna Sonaglia AU - Dennis McGonagle AU - Martina Fabris AU - Maddalena Peghin AU - Davide Pecori AU - Amato De Monte AU - Tiziana Bove AU - Francesco Curcio AU - Flavio Bassi AU - Salvatore De Vita AU - Carlo Tascini TI - Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care AID - 10.1101/2020.05.01.20078360 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.01.20078360 4099 - http://medrxiv.org/content/early/2020/05/10/2020.05.01.20078360.short 4100 - http://medrxiv.org/content/early/2020/05/10/2020.05.01.20078360.full AB - Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine storm”. Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the aim of our study is to address this point.Methods Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19 pneumonia were evaluated in a single centre retrospective study. Patients were divided in two groups: 42 severe cases (TOCI) with adverse prognostic features including raised CRP and IL-6 levels, who underwent anti-cytokine treatments, mostly tocilizumab, and 69 standard of care patients (SOC).Results In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of cases were ventilated and there were 3 deaths (17.8±10.6 days, mean follow up) with 7/26 cases remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection. One fatality occurred in the 15 TOCI cases treated on noninvasive ventilation and 1 serious bacterial superinfection. Of the 69 cases in SOC, there was no fatalities and no bacterial complications. The TOCI group had higher baseline CRP and IL-6 elevations (p<0.0001 for both) and higher neutrophils and lower lymphocyte levels (p= 0.04 and p=0.001, respectively) with the TOCI ventilated patients having higher markers than non-ventilated TOCI patients.Conclusion Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy time in anti-cytokine randomized trials will be key.Funding This research received no external funding.Conflicts of Interest “The authors declare no conflict of interest.”HighlightsThere is an urgent need for markers of prognosis in COVID-19.Higher inflammatory markers best select tocilizumab treatment.The ward based tocilizumab group showed better responses and less infections than ICU tocilizumab group.The former group may be the best for evaluating the impact of anti-cytokine therapy in COVID-19.The known poor risk factors for COVID-19 infection were present in the TOCI treated rather than in the good prognosis standard of care group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, [LQ].